Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Mercy Children's Hospital
1938
mi
from 91732
Toledo, OH
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Mercy Children's Hospital
1938
mi
from 91732
Toledo, OH
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Saint Francis Children's Hospital
1252
mi
from 91732
Tulsa, OK
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Saint Francis Children's Hospital
1252
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Greenville Memorial Hospital
2019
mi
from 91732
Greenville, SC
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Greenville Memorial Hospital
2019
mi
from 91732
Greenville, SC
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Sanford Children's Hospital
1314
mi
from 91732
Sioux Falls, SD
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Sanford Children's Hospital
1314
mi
from 91732
Sioux Falls, SD
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Cook Children's Medical Center
1193
mi
from 91732
Fort Worth, TX
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Cook Children's Medical Center
1193
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Primary Children's Medical Center
573
mi
from 91732
Salt Lake City, UT
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Primary Children's Medical Center
573
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Virginia Commonwealth University
2269
mi
from 91732
Richmond, VA
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Virginia Commonwealth University
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Children's Corporate Center, Division of Neonatology
1724
mi
from 91732
Wauwatosa, WI
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Children's Corporate Center, Division of Neonatology
1724
mi
from 91732
Wauwatosa, WI
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
University of Calgary
mi
from 91732
Calgary,
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
University of Calgary
mi
from 91732
Calgary,
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Jersey Shore University Medical Center
2433
mi
from 91732
Neptune City, NJ
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Jersey Shore University Medical Center
2433
mi
from 91732
Neptune City, NJ
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Montefiore Medical Center
2439
mi
from 91732
The Bronx, NY
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Montefiore Medical Center
2439
mi
from 91732
The Bronx, NY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Emory University
1919
mi
from 91732
Atlanta, GA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Emory University
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Indiana Hemophilia and Thrombosis Center
1792
mi
from 91732
Indianapolis, IN
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Indiana Hemophilia and Thrombosis Center
1792
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Kentucky
1881
mi
from 91732
Lexington, KY
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Kentucky
1881
mi
from 91732
Lexington, KY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Tulane University
1655
mi
from 91732
New Orleans, LA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Tulane University
1655
mi
from 91732
New Orleans, LA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Cornell University
2434
mi
from 91732
New York, NY
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Cornell University
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of North Carolina at Chapel Hill
2189
mi
from 91732
Chapel Hill, NC
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of North Carolina at Chapel Hill
2189
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Cincinnati Children's Hospital
1880
mi
from 91732
Cincinnati, OH
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Cincinnati Children's Hospital
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Oregon
827
mi
from 91732
Portland, OR
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Oregon
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Hemophilia Center of Western Pennsylvania
2121
mi
from 91732
Pittsburgh, PA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Hemophilia Center of Western Pennsylvania
2121
mi
from 91732
Pittsburgh, PA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
North Texas Comprehensive Hemophilia Center
1223
mi
from 91732
Dallas, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
North Texas Comprehensive Hemophilia Center
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Baylor College of Medicine
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Texas Health Science Center at Houston
1352
mi
from 91732
Houston, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Texas Health Science Center at Houston
1352
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Intermountain Hemophilia and Thrombosis Center
570
mi
from 91732
Salt Lake City, UT
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Intermountain Hemophilia and Thrombosis Center
570
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Medical University of Vienna
6093
mi
from 91732
Vienna,
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Medical University of Vienna
6093
mi
from 91732
Vienna,
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
University of Arkansas for Medical Sciences
1461
mi
from 91732
Little Rock, AR
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
University of Arkansas for Medical Sciences
1461
mi
from 91732
Little Rock, AR
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Sidney Kimmel Comprehensive Cancer Center
2302
mi
from 91732
Baltimore, MD
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Sidney Kimmel Comprehensive Cancer Center
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Ohio State University
1959
mi
from 91732
Columbus, OH
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Ohio State University
1959
mi
from 91732
Columbus, OH
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Oregon Health and Science University
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Univ of Pennsylvania
2373
mi
from 91732
Philadelphia, PA
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Univ of Pennsylvania
2373
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Local Institution
5777
mi
from 91732
Pamplona,
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Local Institution
5777
mi
from 91732
Pamplona,
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Emory University
1919
mi
from 91732
Atlanta, GA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Emory University
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Indianda Spine Group
1792
mi
from 91732
Indianapolis, IN
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Indianda Spine Group
1792
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Kansas University Medical Center
1339
mi
from 91732
Kansas City, KA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Kansas University Medical Center
1339
mi
from 91732
Kansas City, KA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
John Hopkins University
2302
mi
from 91732
Baltimore, MD
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
John Hopkins University
2302
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Brigham and Women's Hosp
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
New England Baptist Hospital
2578
mi
from 91732
Boston, MA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
New England Baptist Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Thomas Jefferson University and Rothman Institure Orthopaedics
2375
mi
from 91732
Philadelphia, PA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Thomas Jefferson University and Rothman Institure Orthopaedics
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Universty of Utah
570
mi
from 91732
Salt Lake City, UT
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Universty of Utah
570
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
University of Virginia
2205
mi
from 91732
Charlottesville, VA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
University of Virginia
2205
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Harborview Medical Center
961
mi
from 91732
Seattle, WA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Harborview Medical Center
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
University of Toronto
2158
mi
from 91732
Toronto,
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
University of Toronto
2158
mi
from 91732
Toronto,
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Spine Education Research Institute
808
mi
from 91732
Thornton, CO
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Spine Education Research Institute
808
mi
from 91732
Thornton, CO
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
The Mayo Clinic
1524
mi
from 91732
Rochester, MN
Click here to add this to my saved trials
TRADE-Testosterone Replacement and Dutasteride Effectiveness
Testosterone Replacement and Dutasteride Effectiveness (TRADE)
Status: Enrolling
Updated:  10/30/2017
VA Puget Sound Health Care System
961
mi
from 91732
Seattle, WA
TRADE-Testosterone Replacement and Dutasteride Effectiveness
Testosterone Replacement and Dutasteride Effectiveness (TRADE)
Status: Enrolling
Updated: 10/30/2017
VA Puget Sound Health Care System
961
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen
Status: Enrolling
Updated:  10/30/2017
University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program
1931
mi
from 91732
Ann Arbor, MI
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen
Status: Enrolling
Updated: 10/30/2017
University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program
1931
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/1/2017
Clinical Research Facility
2503
mi
from 91732
Stony Brook, NY
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/1/2017
Clinical Research Facility
2503
mi
from 91732
Stony Brook, NY
Click here to add this to my saved trials
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/1/2017
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/1/2017
Clinical Research Facility
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/1/2017
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/1/2017
Clinical Research Facility
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials